Post Transplant Study

This study has been completed.
Information provided by:
Amgen Identifier:
First received: November 2, 2006
Last updated: December 20, 2007
Last verified: December 2007

Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Condition Intervention
Kidney Tansplant
Secondary Hyperparathyroidism
Drug: Sensipar after Post Transplant

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Amgen:

Estimated Enrollment: 50
Study Start Date: August 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Adults >= 18 years old
  • Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

  • Subjects who received Sensipar before undergoing a kidney transplant
  • Subjects receiving dialysis post-transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00395902

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00395902     History of Changes
Other Study ID Numbers: 20040261, 2004261
Study First Received: November 2, 2006
Last Updated: December 20, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Amgen:

Additional relevant MeSH terms:
Hyperparathyroidism, Secondary
Endocrine System Diseases
Parathyroid Diseases processed this record on October 09, 2015